Breast Cancer Coverage from Every Angle

Anthony D. Elias, MD, on Triple-Negative Breast Cancer: PARP Inhibitors in the Current Treatment Landscape

Posted: Thursday, April 12, 2018

Anthony D. Elias, MD, of the University of Colorado Cancer Center, reviews the role of PARP inhibitors in the current treatment landscape for triple-negative breast cancer and the implications of the now-approved olaparib for gBRCA-mutant breast cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.